Post-Epidemic Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and Associated Factors over a 15-Month Period

Although the acute manifestations of Chikungunya virus (CHIKV) illness are well-documented, few data exist about the long-term rheumatic outcomes of CHIKV-infected patients. We undertook between June and September 2006 a retrospective cohort study aimed at assessing the course of late rheumatic manifestations and investigating potential risk factors associated with the persistence of these rheumatic manifestations over 15 months. 147 participants (>16 yrs) with laboratory-confirmed CHIKV disease diagnosed between March 1 and June 30, 2005, were identified through a surveillance database and interviewed by telephone. At the 15-month-period evaluation after diagnosis, 84 of 147 participants (57%) self-reported rheumatic symptoms. Of these 84 patients, 53 (63%) reported permanent trouble while 31 (37%) had recurrent symptoms. Age ≥45 years (OR = 3.9, 95% CI 1.7–9.7), severe initial joint pain (OR = 4.8, 95% CI 1.9–12.1), and presence of underlying osteoarthritis comorbidity (OR = 2.9, 95% CI 1.1–7.4) were predictors of nonrecovery. Our findings suggest that long-term CHIKV rheumatic manifestations seem to be a frequent underlying post-epidemic condition. Three independent risk factors that may aid in early recognition of patients with the highest risk of presenting prolonged CHIKV illness were identified. Such findings may be particularly useful in the development of future prevention and care strategies for this emerging virus infection

Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response

EA MERS CT3 Enjeu 3International audienceChronic hepatitis C is an independent risk factor for severe drug hepatotoxicity. Successful treatment of chronic hepatitis C may modulate drug hepatotoxicity, as it is associated with a decline in hepatic enzyme release and halts fibrosis progression in HIV/HCV-coinfected patients. The aim of this study was to determine biological and/or clinical determinants of alanine aminotransferase and/or aspartate aminotransferase elevation (>five-fold above the upper limit of normal in patients with normal baseline levels or >3.5-fold increase from baseline in those with increased baseline levels) in a large prospective cohort of HIV/HCV-coinfected patients on HAART who had previously been treated for HCV infection. Median follow-up exceeded five years. Cox proportional hazards models were used. At baseline, 248 patients had been receiving antiretroviral therapy for a mean of 6.3 (+/- 3.2) years. Seventy-one patients (29%) had a sustained HCV viral response (SVR). During follow-up, 66 patients (26.6%) received a second course of HCV therapy and 29 (44%) of them had an SVR. Severe transaminitis occurred in 64 patients (26%). In multivariate analysis, no SVR (HR 33.33, 95% CI 4.54222, P = 0.001) and stavudine-based therapy (HR 2.11, 95% CI 1.123.99, P = 0.018) remained significantly associated with severe transaminitis. A SVR to anti-HCV therapy is thus associated with a markedly reduced risk of severe transaminitis during antiretroviral therapy. Treatment of HCV infection should therefore be a priority in HIV-coinfected patients. Stavudine is associated with an increased risk of severe transaminitis

Trends in Imported Chikungunya Virus Infections in Germany, 2006–2009

Chikungunya virus (CHIKV) has been previously reported in many African and Asian areas, but it recently reemerged strongly in countries bordering the Indian Ocean as well as caused an outbreak in northern Italy. In Germany, where potential CHIKV vectors are not yet established, CHIKV infection is mandatorily notifiable. Cases reported from 2006 through 2009 were analyzed for travel characteristics and demographic factors. 152 cases of symptomatic CHIKV infection were notified. Both sexes were affected, with a median age of 46 years. Over the years, countries of infection largely followed the outbreaks reported from various travel destinations. India and the Maldives were the countries of infection most frequently named. In Sri Lanka, India, and Thailand, which are also frequently named countries of infection for dengue virus, the median age of CHIKV-affected patients was higher than that of dengue fever patients. Taking traveler numbers into consideration, risk of CHIKV infection was higher in the Seychelles and Mauritius than in Thailand and India. Even though substantial underdiagnosis is suspected, this assessment of CHIKV importation to Germany offers valuable information about the details of travel-associated cases. Between 17 and 53 notified cases per year signify that CHIKV would be occasionally available for local transmission in Germany once a vector becomes present. Although CHIKV most often causes a comparatively mild disease, the high median age of notified cases and the higher age than dengue patients support more severe disease courses in older adults. Travelers to all CHIKV endemic areas should protect against mosquito bites. In Germany, CHIKV surveillance will be continued to monitor ongoing importation of the virus and to detect early potential autochthonous cases